Resolutions from the annual shareholders’ meeting 2024

Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.• Approval of the Remuneration Report for 2023• Approval of the remuneration of members of the Board of Directors• Re-election of Cornelis (Cees) de Jong as Chair and Jesper Brandgaard as Vice Chair of the Board of Directors• Re-election of Heine Dalsgaard, Sharon James, Kasim Kutay, Lise Kaae, Kevin Lane, Morten Sommer and Kim Stratton as members of the Board of Directors• Election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting• Approval to renew authorizations to the Board of Directors to implement capital increases • Approval to renew the authorization to the Board of Directors to acquire treasury shares• Approval of authorization to the Board of Directors to distribute extraordinary dividends• Approval of amendments to the Articles of Association • Approval of amendments to the Remuneration PolicyFollowing the annual shareholders’ meeting, the Board of Directors consists of the following members:• Cornelis (Cees) de Jong, Chair• Jesper Brandgaard, Vice Chair• Heine Dalsgaard• Sharon James• Kasim Kutay• Lise Kaae• Kevin Lane• Morten Sommer• Kim StrattonEmployee representatives:• Anne Breum• Anders Hentze Knudsen• Preben Nielsen• Jens Øbro• Karen Louise Lauesen, observer • Kim Ib Sørensen, observer For further information on members of the Board of Directors, please go to www.novonesis.com

Attachment